Navigation Links
Labopharm announces change to Board of Directors
Date:11/7/2008

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Rachel R. Selisker has been appointed to the Board of Directors of the Company to fill the vacancy created by the resignation of James S. Scibetta, who has stepped down for personal reasons. Ms. Selisker will also replace Mr. Scibetta as Chairman of the Audit Committee. Ms. Selisker, a Certified Public Accountant, will bring senior financial advisory expertise in the healthcare industry as well as more than 13 years of experience as chief financial officer of a high growth, international pharmaceutical services company.

Santo J. Costa, Chairman of the Board of Directors of Labopharm, said, "Jim has been a positive influence on Labopharm and has made significant contributions to our Board since joining in 2001. We have benefited greatly from his insights and we wish him well in his future endeavours."

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel SARI containing trazodone for the treatment of major depressive disorder is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Labopharm Reports Results for Third Quarter Fiscal 2008
2. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
3. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
4. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
5. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
6. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
7. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
8. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
9. Labopharm Reports Results for First Quarter Fiscal 2008
10. Labopharm announces details for first quarter results conference call and annual meeting
11. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: